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ABSTRACT
Despite highly toxic treatments, head and neck squamous cell carcinoma (HNSCC) 
have poor outcomes. There is an unmet need for more effective, less toxic therapies. 
Repurposing of clinically-approved drugs, with known safety profiles, may provide a 
time- and cost-effective approach to address this need.
We have developed the AcceleraTED platform to repurpose drugs for HNSCC 
treatment; using in vitro assays (cell viability, clonogenic survival, apoptosis) and 
in vivo models (xenograft tumors in NOD/SCID/gamma mice).
Screening a library of clinically-approved drugs identified the anti-malarial agent 
quinacrine as a candidate, which significantly reduced viability in a concentration 
dependent manner in five HNSCC cell lines (IC50 0.63–1.85 μM) and in six primary 
HNSCC samples (IC50 ~2 μM). Decreased clonogenic survival, increased apoptosis and 
accumulation of LC3-II (indicating altered autophagy) were also observed. Effects were 
additional to those resulting from standard treatments (cisplatin +/– irradiation) alone. 
In vivo, daily treatment with 100 mg/kg oral quinacrine plus cisplatin significantly 
inhibited tumor outgrowth, extending median time to reach maximum tumor volume 
from 20 to 32 days (p < 0.0001) versus control, and from 28 to 32 days versus 2 mg/
kg cisplatin alone. Importantly, combination therapy enabled the dose of cisplatin 
to be halved to 1 mg/kg, whilst maintaining the same impairment of tumor growth. 
Treatment was well tolerated; murine plasma levels reached a steady concentration of 
0.5 µg/mL, comparable to levels achievable and tolerated in humans.
Consequently, due to its favorable toxicity profile and proven safety, quinacrine 
may be particularly useful in reducing cisplatin dose, especially in frail and older 
patients; warranting a clinical trial.
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INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) 
is a debilitating disease comprising 600,000 cases per year 
worldwide [1]. For advanced stage disease, treatment consists 
primarily of either chemoradiotherapy or surgical intervention 
with adjuvant treatment, but results in a poor five year 
survival rate - around only 50% [2]. Due to the high morbidity 
of current treatments, quality of life is severely impaired, with 
evident unmet need necessitating more effective therapies 
with lower toxicity; especially as recent studies examining 
cetuximab as a less toxic alternative for low risk human 
papillomavirus positive HNSCC have shown similar toxicity, 
and lower efficacy compared to cisplatin [3, 4].
Repurposing existing drugs for cancer therapy 
can be valuable due to known safety profiles leading to 
higher success rates and reduced development times, and 
subsequently lower costs compared with the development 
of novel therapeutics. The time taken to gain clinical 
approval for repurposed drugs is usually considerably 
shorter (3–12 years vs 10–17 years for novel therapeutics) 
[5], and success rates for market approval approach nearly 
30% compared to only around 10% for new drugs [6].
We established a multi-stage drug discovery and 
repurposing platform called AcceleraTED. On initial 
screening against HNSCC cell lines, quinacrine was 
identified as a potential hit. Quinacrine, also known as 
mepacrine, was initially utilized as an antimalarial agent as 
early as the 1930s and is considered safe, with only minimal 
side effects, such as headaches and gastrointestinal upset 
[7]. Quinacrine has also been proposed as a treatment for 
numerous other indications, from colitis [8] to prion disease 
[9]. Vassey et al. (1955) [10] first assessed quinacrine as an 
anticancer agent in mice bearing several types of tumor, 
such as fibrosarcoma and carcinoma. More recently, 
effectiveness has been demonstrated in endometrial [11], 
colon [12], non-small cell lung [13] and HNSCC [14].
The mechanisms through which quinacrine exerts 
its anticancer effects are not fully understood. Quinacrine 
is a potent late-stage autophagy inhibitor [15] and has 
been shown to prime cells to the effects of cisplatin via 
apoptosis in cervical and endometrial cancer [16, 17]. 
Further mechanistic insights have been demonstrated 
in HNSCC whereby quinacrine was able to restore the 
function of the tumor suppressive protein, tumor protein 
53 (TP53), leading to enhanced capabilities of initiating 
apoptotic cell death following DNA damage with cisplatin 
chemotherapy [14]; Moreover, quinacrine treatment has 
been shown to suppress phosphoinositide 3-kinase (PI3K), 
protein kinase B (AKT), mechanistic target of rapamycin 
(mTOR) and nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) pathways [18].
Due to promising results from high throughput 
screening and the supportive literature, we sought to 
advance the repurposing potential of quinacrine as an anti-
cancer therapy for HNSCC.
RESULTS
Quinacrine reduces cell viability of HNSCC 
cancer cell lines
The Prestwick library of 1280 FDA-approved drugs 
was initially screened at 10 μM using a high-throughput 
microplate platform. We identified the potential hits and 
completed a confirmatory screen in CAL27 and VU147 
cells (Figure 1A), that revealed the ability of the anti-
malarial drug, quinacrine, tested at 3.3 µM, to reduce cell 
viability by 96.8% and 80.7% in CAL27 and VU147 cells, 
respectively, compared to controls. Even higher reductions 
in cell viability were achieved when using quinacrine in 
combination with 2 µM cisplatin, causing 97.4% and 
90.0% reduction in viability in CAL27 and VU147 cell 
lines, respectively (Figure 1A).
To expand this finding, a larger panel of HNSCC 
cell lines (CAL27, SCC040, FaDu, SCC47 and VU147) 
was exposed to a range of quinacrine concentrations. 
The resulting concentration-response curves illustrate 
that quinacrine effectively inhibits cell viability in a 
concentration dependent manner (Figure 1B) with IC50 
values for cell lines tested ranging from 0.63 to 1.21 
µM (Figure 1B and 1D), which is comfortably within 
clinically achievable concentrations [19–21]. These data 
indicated that quinacrine was a viable candidate for further 
development.
Quinacrine increases the efficacy of cisplatin
HNSCC cell lines showed additional suppression 
of cell viability when quinacrine was combined with 
cisplatin (cell line IC50: 2, 3 or 10 µM), compared to 
quinacrine alone (Figure 1B). The combination of 
quinacrine and standard of care cisplatin was investigated 
further (Figure 2A). To demonstrate a concentration-
dependent reduction in viability, our HNSCC cell lines 
were exposed to increasing concentrations of cisplatin, 
with and without the addition of quinacrine at 0.4, 1.5 
and 3 µM. Quinacrine enhanced the ability of cisplatin to 
suppress cell viability in all cell lines. This reduction was 
more evident at lower concentrations of cisplatin, since 
cisplatin concentrations of 0.1 mM (10–4 M) or above 
resulted in dramatic suppression of viability of all cell 
lines, such that additional suppression by the addition of 
quinacrine was not possible. For example, when treated 
with a cisplatin concentration of 0.3 µM (3 × 10–7 M) 
alone, SCC040 showed cell viability suppression of 
12%, compared to suppression of 17%, 48% and 79% 
following the addition of 0.4, 1.5 and 3 µM quinacrine 
to 0.3 µM cisplatin, respectively. In comparison, at a 
cisplatin concentration of 0.1 mM (10–4M), cell viability 
was reduced by cisplatin alone by 90%, with only 
marginal additional suppression by increasing doses of 
quinacrine.
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Figure 1: (A) Confirmatory screen for hits using CAL27 and VU147 cells exposed to various repurposed drugs at Cmax (or lower), with 
and without cisplatin (n = 3). (B) Cell viability is compared to untreated controls following 72 (cell lines n = 3–7) or 96 (patient-derived 
primary tumor cells n = 6) hours exposure to quinacrine alone (black line) at increasing concentrations and also in the presence of cisplatin 
(red line). IC50 values are highlighted by vertical dotted lines color matched; responses fitted to a five-parameter logistic equation. (C) 
Viability of cells exposed to 1 μM quinacrine compared to untreated controls. (D) Summary of IC50 values (shaded columns) and inverse 
log of the IC50 values (pIC50) of quinacrine and standard error of the mean (SEM) in each cell line, with and without the addition of cisplatin. 
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Quinacrine displays synergy with cisplatin
To confirm the above findings and to assess potential 
synergy of quinacrine when combined with cisplatin, 
Chou-Talalay analysis was undertaken [22]. Synergy 
was observed at lower concentrations of quinacrine and 
cisplatin, as demonstrated by a combination index (CI) 
number less than 1 (Figure 2B) when using a fixed ratio 
of quinacrine to cisplatin concentrations of 1:4 based on 
their IC50 values (IC50 values for quinacrine given in Figure 
1D; cisplatin IC50 ~ 2 µM for CAL27 and SCC040, and 10 
µM for SCC47). Dose reduction indexes (DRI) refer to the 
amount that one drug can be reduced by to maintain the 
same cell viability reduction, termed the fraction affected 
(Fa) (Figure 2C). DRI values higher than 1 indicate that one 
drug can be reduced by adding a second whilst achieving 
the same reduction in cell viability. For example, to 
achieve a 50% reduction in viability (Fa = 0.5) in SCC040 
cells, the concentration of cisplatin can be reduced by 1.27 
times when used in combination with quinacrine. Synergy 
appears to be reduced at higher cisplatin concentrations, 
likely due to the dramatic reduction in cell viability caused 
by high concentration cisplatin treatment alone.
Quinacrine reduces cell viability of primary tumor 
cultures and potentiates the effects of cisplatin
Whilst cell lines are a good model, demonstration 
of anti-tumor activity against primary tumor cells direct 
from patients is much more valuable. Therefore, cells 
established from six HNSCC patients were cultured and 
treated at a range of quinacrine concentrations. All six 
primary patient HNSCC samples tested in vitro exhibited 
similar responses to quinacrine to those observed for the 
cell lines, with a mean IC50 of ~2 µM (Figure 1B and 1D).
When comparing the sensitivity of primary HNSCC 
cultures to the different cell lines at 1 µM quinacrine 
(10–6 M) (Figure 1C), primary cells exhibited cell viability 
suppression of 21.1%, similar to the SCC040 (14.3%) and 
VU147 (35.8%) cells lines, and lower than the CAL27 
(72.3%), FaDu (56.7%) and SCC47 (47.3%) cells.
The primary cell cultures showed additional 
suppression of cell viability when 2 µM cisplatin was 
added to quinacrine (Figure 1B). As described in the cell 
lines above, increasing doses of quinacrine (0.4, 1.5, 3 
and 6 µM quinacrine) enhanced the ability of cisplatin 
to suppress cell viability, more prominently at the lower 
doses of cisplatin (Figure 2A).
Clonal survival is reduced by quinacrine
Clonogenic assays were used to assess whether 
differences in viability were due to reduced clonogenic 
survival of HNSCC cells. All four cell lines (CAL27, 
SCC040, FaDu and SCC47) tested demonstrated a 
concentration-dependent reduction in survival fractions 
when treated with increasing concentrations (0.3, 0.6, 
1.2, 2.4 and 3 µM) of quinacrine (Figure 3A and 3B). The 
relative sensitivities of the different cell lines to 1.2 µM 
quinacrine alone or in combination with cisplatin (0.25 µM) 
and irradiation (0.5 Gy) are displayed in Figure 3C. CAL27 
and FaDu cells had the largest decrease in survival when 
treated with 1.2 µM quinacrine alone, reduced by 88.4% 
and 88.9% compared with untreated controls, respectively. 
SCC040 cells demonstrated 52.9% and SCC47 cells 66.6% 
reduced survival compared with controls.
Further reductions were also evident upon the 
addition of 0.25 µM cisplatin and 0.5 Gy irradiation (Cis-
IR) to 1.2 µM quinacrine (Figure 3C). However, reductions 
in cell viability due to adding Cis-IR to quinacrine 
(adjacent bars on Figure 3A) only reached statistical 
significance (p < 0.05) at quinacrine concentrations 
equal to or lower than 1.2 µM. This is due to the large 
reductions in clonogenic survival caused by higher doses 
of quinacrine, such that radiotherapy and cisplatin could 
not cause significant additional reductions in survival.
Quinacrine induces apoptosis
To understand the mechanisms of quinacrine-
induced cell death in HNSCC cell lines, we first 
investigated apoptosis using the Annexin V apoptosis 
assay. The table in Figure 4A demonstrates how various 
groups of live, dead and dying cells were identified by 
flow cytometry. Cells that are alive (within the lower 
left quadrant) became slightly more dispersed following 
the addition of quinacrine (32) compared to those not 
receiving quinacrine (green). This is caused by the 
DNA-intercollation and subsequent auto-fluorescence of 
quinacrine within the FITC channel. These qualities do not 
interfere with assessment of apoptotic and non-apoptotic 
cell death, as quinacrine emits light at 488 nm, which is 
spectrally distinct from PI fluorescence (610 nm) and 
Annexin V-Cy5 fluorescence (680 nm).
CAL27, SCC040, SCC47 and FaDu cells were 
exposed to cisplatin alone (2 µM and 10 µM), increasing 
concentrations of quinacrine (0.6, 1.2, 1.8 and 2.4 
µM) alone or a combination of increasing quinacrine 
concentrations and 2 µM cisplatin for 48 hours prior to 
Annexin V/PI quantification. CAL27, FaDu and, to a 
lesser extent, SCC040 cells showed a dose-dependent 
increase in Annexin V positive and PI positive cells with 
increasing quinacrine concentrations (Figure 4B). FaDu 
cells showed the largest increase in apoptosing cells and 
apoptotic cell death when exposed to quinacrine, with 
39.4% of cells displaying Annexin V positivity when 
treated with 2.4 µM quinacrine alone and 49.1% positive 
when treated with 2.4 µM quinacrine in combination with 
2 µM cisplatin. CAL27 cells also showed considerable 
apoptosis following 2.4 µM quinacrine treatment alone, 
with 30.1% cells positive for Annexin-V. Interestingly, 
SCC47 cells did not show sensitivity towards quinacrine 
or 2 µM cisplatin alone, reflecting the diversity in cell 
lines utilized.
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Figure 2: (A) Concentration response curves of cell lines (n = 3–4) and patient-derived primary tumor cells (n = 6) to increasing 
concentrations of cisplatin (red line) with the addition of 0.4 (black line), 1.5 (green line), 3 (purple line) or 6 µM (grey line) quinacrine. 
Vertical lines highlight IC50 values color matched; responses fitted to a five-parameter logistic equation. (B) Fraction affected vs Combination 
Index (Fa-CI) plot for each cell line, produced using CompuSyn. Concentrations range from 1/32x – 2x IC50 for quinacrine (Q), and from 
1/8x – 8x IC50 for cisplatin (C), maintaining a ratio of 1:4 Q:C. Data points below 1 (dotted line) represent synergy (n = 3). (C) Dose 
reduction index (DRI) table for CAL27, SCC040 and SCC47 cell lines (n = 3). Green indicates DRI values > 1 (favorable reduction); 
orange indicates DRI values <1 (less favorable reduction).
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Autophagic flux is altered by quinacrine treatment
The ability of quinacrine to mediate autophagy has 
been shown in other cancer types, but not in HNSCC to 
date. We therefore analyzed LC3 levels to determine 
whether quinacrine affects autophagic flux within CAL27 
and SCC040 cells (Figure 5). LC3-I is constitutively 
expressed within the cytosol and converted to LC3-II 
upon recruitment to autophagosome membranes; therefore 
LC3-I/LC3-II is often utilized as a marker of autophagy 
Figure 3: Clonogenic survival of cell lines exposed to increasing concentrations of quinacrine, with and without 0.25 
μM cisplatin and 0.5 Gy irradiation (Cis+IR) for 24 hours (n = 3–4). (A) Values are presented as a percentage of untreated 
controls. A two-way ANOVA with Dunnett’s multiple comparison test was performed and P-values indicated on the graphs as follows: *p < 
0.05, **p < 0.01, ***p < 0.005, ****p < 0.001. Stars directly above bars correspond with differences from their relevant control plates (Unt or 
Cis-IR). Stars above lines show differences between the treatments indicated. (B) Representative scanned plates showing SCC47 colonies 
surviving following treatment. (C) Relative survival of cells exposed to 1.2 μM quinacrine compared to their relevant control plates (Unt 
or Cis-IR), with and without Cis-IR. 
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initiation. LC3-II is later degraded within autolysosomes 
upon completion of autophagy [23]. Quinacrine has been 
shown to sequester hydrogen ions within autolysosomes, 
which raises pH and impairs the breakdown of cellular 
components and therefore inhibits completion of autophagy, 
leading to a build-up of LC3-II [15] (Figure 5C).
Figure 4: Assessment of cell death following 48 hour exposure to quinacrine +/- cisplatin. (A) Representative scatter plots 
highlighting different cell populations following treatment of CAL27 cells. The table describes cells within each quadrant. (B) Total apoptotic 
and dead cell populations were quantified using Kaluza software and split into Annexin V –ve/ PI +ve (non-apoptosing dead cells), Annexin 
V +ve/ PI +ve (dead through apoptosis) and Annexin V/ PI –ve (undergoing apoptosis). One Way ANOVA followed by Dunnett’s multiple 
comparisons test was performed between each treatment and the appropriate control (Untreated [UNT] or 2 μM Cisplatin [Cis]) (n = 3–6). 
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Cells were exposed to cisplatin alone, quinacrine 
at 1.2, 1.8 and 2.4 µM alone or 1.8 µM quinacrine plus 
2 µM cisplatin for 48 hours. Expression of LC3-I and 
LC3-II was then determined by Western blotting. Both 
cell lines displayed a dramatic increase in LC3-II at all 
concentrations of quinacrine treatment tested (Figure 5A–
5B), whereas LC3-I remained unchanged in CAL27 cells 
and showed a non-significant increase in SCC040 cells. 
The accumulation of LC3-II in this setting is therefore 
indicative of quinacrine inhibiting the completion 
of autophagy. In contrast, cisplatin addition did not 
significantly alter levels of LC3-I or LC3-II in either cell 
line tested.
We assessed p53 expression in both SCC040 
and CAL27 cell lines following 48 hours exposure 
to quinacrine (1.2, 1.8 and 2.4 µM) alone and with 1.8 
µM quinacrine + 2 µM cisplatin to assess the potential 
influence of p53 on apoptosis in these cell lines. CAL27 
cells possess a mutation in p53, rendering it non-functional 
[24]. They demonstrated no change in expression of p53 
or the downstream protein p21 following quinacrine or 
cisplatin treatment (Supplementary Figure 1). SCC040 
cells express wild-type p53 [25]. Again, no change in p53 
or p21 expression was seen as a result of quinacrine or 
cisplatin treatment after 48 hours (Supplementary Figure 
1) This would indicate that the mechanisms of action of 
quinacrine, within our experimental setup, are likely to be 
independent of TP53 status and p53 function.
Tumor xenograft growth is impaired by 
quinacrine and cisplatin
To substantiate the findings in the HNSCC cell 
lines and in patient-derived tumor cells, NSG mice 
bearing FaDu xenograft tumors were treated orally with 
100 mg/kg quinacrine every two days, with and without 1 
mg/kg or cisplatin (2 mg/kg or 1 mg/kg) via intraperitoneal 
injection on days 4, 8 and 12. Tumor volumes at day 19, 
when the first control animal was culled, show reductions 
in the size of treated tumors, mainly in those treated with 
quinacrine and 2 mg/kg cisplatin (p = 0.0001) (Figure 6A 
and 6B).
Quinacrine alone showed early inhibition of 
tumor growth, and modestly extended the mean time 
needed to reach maximum volume by 2 days (from 20 
to 22 days), compared to untreated control (Figure 6A 
and 6C). In comparison, higher dose cisplatin (2 mg/
kg) alone extended the mean time to reach maximum 
tumor volume by 8 days, from 20 to 28 days compared 
to untreated control. Quinacrine was particularly effective 
when combined with high dose cisplatin, whereby the time 
taken for tumors to reach their maximum volume could be 
extended by 12 days, taking a median of 32 days compared 
to 20 days for untreated controls to reach a tumor volume 
of 1000 mm3 (p < 0.0001), and was also significantly 
higher than the time taken to reach maximum tumor 
volume in the group treated by quinacrine alone, from 22 
days to 32 days (p = 0.0002). There was a difference in the 
time needed to reach maximum tumor volume between 
the combined quinacrine and 2 mg/kg cisplatin group and 
the 2 mg/kg cisplatin alone group of 4 days, however this 
did not reach statistical significance (p = 0.6), possibly 
due to the small sample size and corrections for multiple 
comparisons.
The Kaplan-Meier plot (Figure 6D) further 
emphasizes the extended time for treated tumors to reach 
their maximum tumor volume (MTV) when mice were 
treated with cisplatin (2 mg/kg) and quinacrine, even 
though one animal was culled early due to a deterioration 
of their overall condition and not due to tumor volume. 
The Hazards ratio for time taken to reach MTV in the 2 
mg/kg cisplatin and quinacrine group compared to the 2 
mg/kg cisplatin alone group was 0.4 (95% CI, Mantel-
Haenszel test).
Importantly, the in vitro experiments demonstrated 
that the synergy between quinacrine and cisplatin was 
highest at lower doses of cisplatin, where quinacrine 
potentiated the effect of cisplatin most. At higher 
concentrations of cisplatin tumor kill was so high that 
there was little possibility for quinacrine to add an effect. 
We therefore also tested the combination of quinacrine 
with a lower dose of cisplatin (1 mg/kg – half the higher 
dose used). At that concentration, quinacrine and 1 mg/
kg cisplatin resulted in the same growth rate as 2 mg/kg 
cisplatin alone, indicating that by adding quinacrine, the 
dose of cisplatin can be halved whilst maintaining the same 
anti-cancer efficacy, which could have significant benefits 
to patients by reducing toxicity related side effects.
Quinacrine and cisplatin were well tolerated 
throughout the in vivo experiment. The weights of mice 
remained well within the 20% weight loss cut-off (Figure 
6E). A slight yellowing of the skin of animals treated 
with quinacrine was apparent due to the auto fluorescent 
properties of the drug (Figure 6F).
Quinacrine is present in plasma and tumor tissue
Quinacrine was administered at 100 mg/kg to mice 
every 48 hours via oral gavage. To establish whether a 
steady, therapeutic concentration was maintained within 
the circulation of mice receiving oral quinacrine treatment, 
blood samples were taken 48 hours after the 9th dose 
of quinacrine (on day 19 of the toxicity experiment). 
Analysis carried out by LC-MS (Supplementary Figure 2) 
revealed that even 48 hours after the last dose, plasma 
concentrations of 0.5 mg/mL were still present (Figure 
6G), equating to 1.25 µM, a dose that had resulted in a 
significant response using the alamarBlue® viability 
assay in all cell lines tested (Figure 1B–1D) and initiated 
apoptosis in CAL27 and FaDu cells (Figure 4B).
To establish whether quinacrine successfully 
entered tumors from the blood, sections were taken and 
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quinacrine fluorescence visualized at 488nm. Tumor 
samples from mice receiving quinacrine treatment showed 
clear fluorescence throughout their tumors, whereas those 
receiving only control treatment did not (Figure 6H); thus 
confirming that quinacrine is able to reach tumor tissue 
following oral administration.
Figure 5: Western blot analysis of autophagy induction. (A) Representative Western blots showing levels of LC3-I and LC3-II in 
CAL27 and SCC040 cells following 48 hours exposure to quinacrine at increasing concentrations (1.2, 1.8 and 2.4 μM), 1.8 μM quinacrine 
with 2 μM cisplatin and 2 μM cisplatin alone. GAPDH was used as a loading control. (B) Histograms from ImageJ densitometry analysis 
representing the quantitative changes in LC3 levels in each of the cell lines. LC3-II/LC3-I demonstrates the relative levels of the two 
proteins. Each band was normalized to an internal untreated control band. P-values above bars highlight differences vs untreated control 
cells following one-way ANOVA followed by Dunnet’s multiple comparisons test (n = 3). (C) Schematic showing the recruitment of LC3-II 
to autophagosomal membranes and the ability of quinacrine to exert its inhibitory affects and prevent completion of autophagy.
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Figure 6: (A) Tumor growth in mice bearing FaDu tumors treated with 100 mg/kg quinacrine and or cisplatin (1 or 2 mg/kg, as indicated), 
n = 5–6 per group. (B) Tumor volumes on day 19 (n = 5–7 per group). (C) Time taken for tumors to reach maximum tumor volume 
(MTV) with median days for each treatment indicated on bars. (D) Kaplan-Meier plot showing the proportion of animals with tumors 
below MTV over time. *Star indicates a quinacrine + 2 mg/kg cisplatin animal being culled for reasons other than tumor size (n = 5–7 
in each group). A log-rank (Mantel-Cox) test showed a significant difference between groups, represented on the graph. (E) Weights of 
mice over the experiment. (F) Slight yellowing of the skin caused by quinacrine treatment (right) next to a vehicle-treated animal (left). 
(G) Concentrations of quinacrine in mouse plasma 48 hours post-gavage treatment on day 19 of treatment (n = 5). (H) Cross sections of 
representative tumor sections taken at the end of the experiment from vehicle and quinacrine-treated mice showing autofluorescence in the 
FITC channel of cells incorporating quinacrine into their DNA (n = 3).
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DISCUSSION
Our data support the use of quinacrine as a potential 
treatment option for HNSCC. We have shown that in vitro 
quinacrine (at clinically relevant concentrations) reduces 
viability of head and neck cancer (HNC) cell lines and 
primary cultures, decreases clonogenic survival, increases 
apoptosis and inhibit autophagy. Importantly, effects were 
in addition to those resulting from standard treatment 
(cisplatin +/– irradiation), and importantly we have 
demonstrated synergy of quinacrine with cisplatin.
Quinacrine’s ability to promote apoptosis of cancer 
cells has been previously reported and mechanisms for this 
have been suggested. Firstly, it is thought that quinacrine 
enhances the binding of the TRAIL ligand to Death 
Receptor 5 (DR5) via formation of a stable quinacrine-
TRAIL-DR5 complex [26]. In addition to this, quinacrine 
has been shown to restore deficient, wild-type p53 
function in UM-SCC HNSCC cell lines by inducing TP53 
mRNA and protein expression. Hence, as p53 can regulate 
cisplatin-induced cell death by several mechanisms, this 
increased their sensitivity to cisplatin [14]. The ability of 
quinacrine to restore p53 function would be promising 
in HNC as the majority of HNSCC that retain wild-type 
TP53 genotype have previously been shown to exhibit 
low immunostaining for TP53 protein [27]. SCC040 cells 
express wild type p53, whilst CAL27 cells express mutant 
p53 (p.H193L). In our study, no change in p53 expression 
or its downstream protein p21 was observed in CAL27 and 
SCC040 cells following 48 hours of quinacrine exposure. 
This may be because both cell lines expressed sufficient 
levels of p53 at baseline. Mechanisms independent of p53 
are therefore likely to be driving the majority of apoptosis 
within these two cell lines.
The divergent proportions of apoptosis seen 
between the HNC cell lines in this study may be due to 
intrinsic differences in the expression of proteins within 
the apoptotic pathway. For example, the poor prognostic 
marker and anti-apoptotic protein, MCL1 (Myeloid Cell 
Leukemia Sequence 1 [BCL2-related]), is a target of 
quinacrine, as shown in anaplastic thyroid cancer [28]. 
Low MCL1 expression, as in non-malignant tissue, 
corresponds with lack of response to drug treatment.
Quinacrine has previously been shown to cause the 
build-up of dysfunctional autolysosomes as evidenced 
by accumulated LC3-II [29]. Our study supported these 
findings with dramatic increases in LC3-II protein 
expression in HNSCC cell lines following quinacrine 
exposure. In ovarian cancer, disruption of autophagy 
sensitizes cells to autophagic cell death and apoptosis via 
a p53-independent pathway when exposed to cisplatin 
[17]. We hypothesize that quinacrine’s ability to impede 
autophagy increases stress within HNSCC cells, thus 
inducing apoptosis.
In vivo quinacrine treatment was well tolerated and 
data presented here is the first to show that quinacrine, at 
clinically achievable concentrations is able to reduce tumor 
burden in mice, extending median time to reach maximum 
tumor volume. Analysis of plasma concentrations levels of 
quinacrine during these studies showed a steady state blood 
plasma concentration of around 0.5 mg/ml (~ 1.25 µM). 
This is a concentration at which all cells tested in vitro were 
responsive to quinacrine, including primary tumor cells 
from HNSCC patients. Due to its relatively long half-life 
(5–14 days) quinacrine is maintained at a therapeutic dose 
48 hours after dosing, indicating a large treatment window 
allowing for flexible dosing schedules [30].
Importantly, our in vivo data has shown that 
quinacrine is able to penetrate the target tissue following 
oral administration. Drug, also, accumulated in other 
tissues, including the skin and liver, causing some yellow 
discoloration; this has been reported previously and is 
cleared rapidly following cessation of quinacrine treatment 
[11]. We demonstrated that combination of quinacrine with 
cisplatin improved tumor growth inhibition compared to 
quinacrine or cisplatin alone. Importantly, the combination 
of quinacrine with cisplatin enabled the dose of cisplatin 
to be halved, whilst maintaining the same impairment of 
tumor growth.
Extensive, long-term data on safety of quinacrine is 
available due to of its widespread use by United States 
soldiers during the Second World War; three million 
people treated with the drug for up to four years [30]. 
These data show that quinacrine is safe and lacks serious 
side-effects. Low toxicity in non-cancerous tissue is 
extremely beneficial when identifying novel cancer 
treatments, as adverse off-target effects often limit the 
use of toxic chemotherapeutics; quinacrine has previously 
been demonstrated to have very low toxicity in normal 
mononuclear cells [31]. Quinacrine has been tolerated well 
in humans at doses up to 800 mg/day for a 70 kg adult [11]. 
The dose used in our in vivo efficacy study of 100 mg/kg 
equates to a human dose of 568 mg, which is well within 
the levels clinically tolerated [11, 32]. Four early phase 
clinical trials have been initiated since 2006 examining 
the safety and efficacy of quinacrine in the treatment of 
lung (NCT01839955), colorectal (NCT01844076), renal 
(NCT00574483) and prostate cancer (NCT00417274), 
of which three are complete and one has reported results 
[33]. In the latter study, all patients completed treatment, 
indicating the tolerability of quinacrine.
Cisplatin is a highly toxic chemotherapeutic agent, 
which can cause severe nausea and vomiting, renal failure 
and cardiovascular damage, among other side-effects 
[34]. Therefore, reducing and replacing cisplatin use, 
even partially, whilst maintaining efficacy could be of 
considerable benefit to patients. This is especially relevant 
in older or unfit patients, who currently may be excluded 
from receiving cisplatin at current doses due to its poor 
tolerability. It is also particularly important as up until 
recently cetuximab was used as an alternative to cisplatin 
in less fit patients with HNSCC. However, two recent 
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randomized studies have demonstrated that cetuximab is 
not only as toxic as cisplatin, but is also less effective in the 
treatment of HPV+ HNSCC [3, 4], and therefore there is 
an ongoing unmet need for treatments with lower toxicity.
Our study has an intrinsic limitation that all in 
vitro, and ex vivo, studies have as the cells are studied in 
artificial environments, resulting in the disruption of some 
interactions that regulate biological activity. In order to 
address these limitations, we also tested the efficacy of 
quinacrine in vivo, using a HNC xenograft mouse model. 
We used subcutaneous xenograft mouse models due their 
reproducibility, reliable assessment of tumor growth and 
response to treatment. However, all mouse models have 
well recognized limitations as human cancer models [35].
The data presented in this paper, combined with 
evidence from additional cancer types, support the study 
of quinacrine in addition to standard chemotherapy for 
improving outcome in HNSCC patients, especially with 
the aim of using the combination in patients who cannot 
tolerate the full dose of cisplatin. Quinacrine with its 
wealth of safety data reduces the potential risk to patients 
and clinical trial sponsors, therefore making it an appealing 
candidate to move forward into clinical assessment with 
cisplatin. We are in the process of initiating a clinical trial 
in HNSCC patients for the assessment of quinacrine as an 
anti-cancer treatment.
Significance statement
Head and neck cancer (HNC) patients have limited 
treatment options, often associated with severe, potentially 
life-threatening, side effects. We demonstrated efficacy of 
quinacrine and synergy with standard-of-care cisplatin 
against HNSCC in vitro. Notably, our study is the first 
to demonstrate that quinacrine is able to reduce tumor 
burden in mice bearing HNSCC xenograft tumors, using 
concentrations that are clinically relevant. Importantly, 
combination with quinacrine enabled the dose of cisplatin 
to be halved in mice, whilst maintaining the same 
impairment of xenograft tumor growth. As quinacrine has 
little toxicity, this suggests potential therapeutic benefit in 
older and frail patients.
MATERIALS AND METHODS
AcceleraTED drug repurposing platform
At the Institute of Head and Neck Studies 
and Education (InHANSE), we have developed the 
‘AcceleraTED’ drug repurposing platform. It aims to assess 
the efficacy of libraries of Food and Drug Administration/ 
European Medicines Agency (FDA/EMA)-approved drugs 
as anti-cancer agents against HNSCC, with the aim of 
rapidly progressing promising candidates into the clinic.
The platform consists of five main stages, each 
with go/no go criteria to allow progression of a hit to 
the next stage: The first stage utilizes a high-throughput 
alamarBlue® (ThermoFisher Scienctific) cell viability 
screen to identify compounds that suppress viability of 
HNSCC cell lines. We use a cut off of 50% suppression 
of viability or more when the drug is used at clinically-
achievable concentrations [Cmax (maximum serum 
concentration observed in patients) or lower]. Stage two 
validates the findings of the initial screen using a panel 
of well-characterized HNSCC cell lines and then assesses 
concentration responses, clonogenic survival, and the 
ability of compounds to induce apoptotic cell death 
and autophagy. Stage three further validates results by 
assessing concentration-response curves using primary 
cell cultures grown directly from HNSCC patients. The 
fourth stage undertakes in vivo testing, whereby initial 
toxicity is established, followed by evaluation of efficacy 
against HNSCC xenograft tumors. Following successful 
completion of these stages, stage five intends to test 
the safety of compounds in combination with standard 
treatment in early-phase clinical trials.
More detail on individual assays is given below. 
All experiments represent a minimum of at least three 
independent repeats, as indicated.
Drugs and chemicals
All drugs and chemicals were sourced from Sigma 
(now Merck) unless otherwise stated. Concentrations used 
were based upon clinically-achievable concentrations 
described previously in the literature based on clinically 
prescribed doses. Solubility information was taken from 
documentation accompanying the drug library or PubChem.
Cell cultures
The human papillomavirus (HPV) negative cell 
lines CAL27 (ACC-446; DSMZ), SCC040 (UPCI-
SCC-040; ACC-660; DSMZ) and FaDu (ATCC HTB-
43), and HPV positive cell lines SCC47 (UM-SCC-47; 
Millipore) and VU147 (gifted from Prof. J. de Winter, 
Amsterdam, Netherlands) were used. The cell lines were 
cultured using Dulbecco’s Modified Eagle’s Medium-
HEPES Modification (DMEM) supplemented with 10% 
fetal bovine serum (FBS), 1% L-glutamine, 1% penicillin/ 
streptomycin and 1% non-essential amino acids (NEAA) 
at 37°C. All cell lines were verified mycoplasma negative 
every six months, along with annual authentication via 
Short Tandem Repeat (STR) profiling.
Patient-derived primary cell cultures
Tumor biopsies were obtained from HNSCC patients 
undergoing diagnostic biopsy or tumor resections, and 
who were consented under the Human Research Authority 
(HRA) Human Tissue Act 2004 ethics approval number 
16/NW/0265. Tissue samples were collected and within 30 
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minutes washed five times in transport medium (DMEM 
with HEPES modification supplemented with 10% FBS, 
2 mM L-glutamine, 50 μg/ml penicillin/ streptomycin, 
50 μg/mL gentamicin, 10 μg/mL clindamycin, 5 μg/ml 
amphotericin B and 5 μg/mL chloramphenicol). Following 
washing, the tissue was disaggregated using sterile 
scalpels, transferred to serum-free media (SFM) (as part 
of a kit including BPE and EGF), supplemented with 50 
μg/mL penicillin/ streptomycin, 50 μg/ml gentamicin, 5 
μg/mL amphotericin B and 10 μM ROCK inhibitor (Y-
27632) (Bio-techne, Tocris) and grown on rat tail collagen 
(8 μg/mL) coated plates at 37°C. After 24 hours, media 
was replaced and cells left for 7 days to assess growth.
Cell viability and proliferation
The alamarBlue® (Invitrogen) cell viability assay 
was utilized to measure the relative viability of cells as a 
measure of proliferation. AlamarBlue® contains a blue dye 
called resazurin that changes to a pink, highly fluorescent 
form in the presence of metabolically active cells, giving 
a quantitative measure of the relative number of viable 
cells. Cells were seeded in 96 well plates at pre-optimized 
densities. After 24 hours, appropriate treatments were added 
to wells and cells were incubated for a further 68 hours (cell 
lines) or 92 hours (patient-derived primary cells). These 
time differences reflect the growth rate of cells and allow 
for the time required to undergo two cell divisions. Cells 
were then incubated for 4 hours with 20 μL (10% of final 
volume) alamarBlue® reagent per well. Fluorescence was 
then measured at 550 nm. All relative fluorescence unit 
(RFU) values were normalized by deducting values from 
paired plates containing only media and drug (but no cells) 
and plotted as a percentage of untreated. All assays were 
carried out in triplicate and the mean values calculated.
Initial drug screen
The Prestwick Chemical Library® was used for 
the initial screen for this study. The library consists of 
1280 FDA/EMA approved, off-patent drugs [36]. For the 
initial, high-throughput screen, drugs were tested at 10 μM 
concentrations using the alamarBlue® cell viability assay 
on at least 2 HNSCC cell lines for each drug.
Those drugs achieving at least 50% suppression of 
cell viability in both cell lines were considered promising 
and subsequently analyzed in a secondary confirmatory 
screen using Cmax (or lower) values in alamarBlue
® 
cell viability assays using CAL27 (HPV-) and VU147 
(HPV+) HNSCC cell lines. Again, hits were confirmed 
as compounds that reduced cell viability by 50% or more 
compared to untreated controls.
Concentration curves
Concentration-response curves were generated 
for quinacrine for each of five HNSCC cell lines and on 
patient-derived primary cells, following treatment with 
both quinacrine alone and in combination with cisplatin 
using alamarBlue®. In addition, response to increasing 
cisplatin concentrations in combination with 0, 0.4, 1.5, 3 
and 6 μM quinacrine was also assessed. Each experiment 
was carried out in triplicate and normalized to untreated 
control wells containing only media and drug.
Synergy experiments
CAL27, SCC040 and SCC47 cells were plated in 
96 well plates and exposed to fixed ratios of quinacrine 
and cisplatin in relation to their IC50 values. Cells were 
exposed to drugs for 72 hours and cell viability was 
quantified using alamarBlue®. The optimal ratio was found 
to be a 1 to 4 ratio of quinacrine to cisplatin. Chou-Talalay 
analysis was then carried out using CompuSyn software 
(Nick Martin, MIT, Cambridge, MA). This calculates 
the fraction affected (Fa), a combination index (CI) and 
dose-reduction index (DRI). In our experiments, the dose 
reduction index refers to how many times the dose of one 
drug can be reduced when in combination with another 
drug and still elicit the same efficacy. A combination index 
value less than one is indicative of a synergistic effect; a 
value of one infers additivity and values above one suggest 
sub-additive responses.
Cell survival and proliferation
To assess the survival of HNSCC cells and their 
ability to proliferate to produce clonal colonies following 
24 hour drug exposure, clonogenic assays were utilized. 
CAL27, SCC040, FaDu and SCC47 cells were plated at 
optimized seeding densities in 10 cm plates and treated 
24 hours later with a range of quinacrine concentrations 
+/– 0.25 µM cisplatin and 0.5 Gray irradiation. Culture 
medium was replaced after a further 24 hours and then 
the cells were left to establish colonies in the absence of 
any treatment. After 10–14 days depending on the cell 
line, colonies were stained using crystal violet (0.5% w/v), 
containing glutaraldehyde (6% v/v). Colonies were counted 
using Image J software. Due to the nature of growth of 
SCC47 growth, with less dense colonies, plates could 
not be analyzed on Image J and were counted manually. 
Plating efficiency was calculated by dividing the number 
of colonies formed by the number of cells seeded, which 
was then used to determine the survival fraction of each 
treatment normalized to the untreated control.
Apoptotic cell death analysis using Annexin V/
propidium iodide flow cytometry
The ability of quinacrine to induce apoptosis was 
investigated using Annexin V/ propidium iodide (PI) assays. 
The Annexin V antibody binds to phosphatidylserine on the 
outer surface of cells undergoing apoptosis. PI is added to 
highlight all dead cells, regardless of mechanism of cell 
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death. CAL27, FaDu, SCC040 and SCC47 cells were 
seeded in 6 well plates at the following number of cells per 
well: 15 × 105 CAL27; 1 × 105 SCC040; 1.4 × 105 FaDu; 
3 × 105 SCC47. Drug treatments were added 24 hours 
later. After 48 hours incubation, cells were harvested and 
analyzed using Annexin V-Cy5 (PromoCell, Heidelberg, 
Germany) and the Dead Cell Apoptosis Kit (ThermoFisher 
Scientific, MA, USA) as per manufacturer’s instructions. 
The percentage of apoptotic cells was determined by 
Annexin V-Cy5 positivity using flow cytometry. From 
each sample, 30,000–50,000 events were recorded using 
an LSR II flow cytometer (BD Biosciences, CA, USA). 
Quantification as a percentage of the overall live and dead 
cell populations was carried out using Kaluza Software 
(Beckman Coulter, CA, USA).
Western blot immunoreactivity analysis
To investigate the effect that quinacrine exerts on 
autophagy, protein expression of the autophagy marker, 
Microtubule-associated proteins 1A/1B Light Chain 
3B (LC3), was assessed by immunoreactivity Western 
blotting. All reagents were obtained from BioRad unless 
otherwise stated. Expression of the tumor suppressor 
protein, p53, was also visualized. Ten cm plates were 
seeded with 1.2 × 106 CAL27 or SCC040 cells per plate. 
After 24 hours, the appropriate drugs were added to the 
plates. Forty-eight hours after the addition of drugs, 
cells were harvested in RIPA buffer (Thermo Scientific) 
supplemented with protease and phosphatase inhibitors 
and EDTA (Thermo Scientific). Membranes were exposed 
to primary antibodies diluted in 5% BSA-TBS-T as 
follows: LC3 1:500 (Novus Bio, NB100-2331); β-actin 
1:5000 (Abcam ab15580); p53 1:1000 (Santa Cruz, sc-
126); p211:1000 (Santa Cruz, sc-53870). Following 
overnight incubation, membranes were exposed to anti-
rabbit secondary antibody 1:5000 (Promega, W4011) or 
anti-mouse secondary antibody 1:1000 (DAKO, P0447) 
as appropriate and imaged using a ChemiDoc Imaging 
system. Densitometry was carried out using ImageJ 
software. LC3-II accumulation following treatment was 
used to indicate the impairment of cells to complete 
autophagy and therefore accumulate autophagosomal 
markers.
In vivo efficacy study
In the fourth, in vivo validation stage of the 
AcceleraTED platform, we examined overt toxicity 
and the anti-tumor efficacy of quinacrine, alone and in 
combination with cisplatin. Male NOD/SCID/gamma 
(NSG) mice (Charles River) were kept in 12 hour light 
and 12 hour dark cycles in individually ventilated cages. 
All procedures were carried out in accordance with the UK 
Home Office Animal (Scientific Procedures) Act 1986 and 
approved by the local University of Birmingham Ethical 
Review Committee. Mice were maintained on mouse feed 
and water, ad libitum, and were at least 6 weeks old at the 
start of treatment.
NSG male mice were implanted with 5 × 106 FaDu 
HNSCC cells, suspended in serum-free medium, by 
subcutaneous injection into the right flank. Tumors were 
given three days to become established, at which point 
mice were randomly allocated into five treatment groups 
as follows: (1) control (PBS); (2) 200 mg/kg quinacrine 
dissolved in PBS via daily oral gavage from day 4 
onwards; (3) 2 mg/kg cisplatin dissolved in PBS given 
via intraperitoneal (IP) injection on days 4, 8 and 12; (4) 
1 mg/kg cisplatin with 200 mg/kg quinacrine as in 
groups two and three; (5) 2 mg/kg cisplatin with 
200 mg/kg quinacrine as in groups two and three. Animals 
were monitored daily for signs of ill health. Tumor 
measurements were taken using calipers and volumes 
calculated using the formula L × W2.
Mice were culled once tumors reached a maximum 
of 1250 mm3. Tumors were then excised and paraffin-
embedded or frozen for subsequent analysis. Each group 
contained 6–8 animals. When displaying tumor growth 
over time, to gain an understanding of efficacy over a 
longer period, data was plotted until at least 5 animals 
per group remained. When fewer animals remained in a 
group, no more data were plotted. Data from all animals, 
however, were included when summarizing tumor 
volumes at day 19 and displaying time taken to reach 
maximum tumor volume (MTV).
Circulating quinacrine quantification
To quantify minimum steady state plasma levels of 
quinacrine, up to 100 µL blood was taken from the tail vein 
of each animal 48 hours after the last oral dose at the end 
of the second week of dosing during toxicity experiments. 
Samples were spun for 10 minutes at 123 × g to separate the 
plasma, which was stored at –80ºC until analysis.
Blood analysis for circulating quinacrine using 
HPLC-MS
Blood was taken from mice 48 hours following their 
ninth dose of quinacrine (day 19 of the toxicity study) 
via saphenous vein bleed. Blood was then centrifuged at 
500 × g to separate plasma from cells. Plasma levels of 
quinacrine were quantified using ultra-high performance 
liquid chromatography (HPLC) combined with mass 
spectroscopy (MS) (Supplementary Figure 2). For detailed 
methods, see Supplementary Appendix.
Visualizing drug penetration of tumors
To establish whether quinacrine was able to penetrate 
into tumor tissue, fresh frozen tumors were sectioned using a 
cryostat (Bright Instruments, Huntingdon, UK) and mounted 
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using anti-fade mountant (Thermo Fisher Scientific, MA, 
USA) containing DAPI (4′,6-diamidino-2-phenylindole). The 
fluorescence caused by quinacrine was then imaged at 488 
nm using an epifluorescence microscope.
Statistics
Data were represented as mean ± standard error of 
the mean (SEM) unless otherwise described. One-Way 
ANOVA followed by Dunnett’s or Tukey’s corrections for 
multiple comparisons was used to analyze all data other 
than for clonogenic analysis, which utilized Two-Way 
ANOVA. Each treatment value was compared to that of 
the appropriate control as indicated in the figures. Relative 
changes were calculated by dividing the value of the drug-
treated sample by that of the untreated sample. Kaplan-
Meier analyses were used to show differences in survival 
between all groups. A Mantel-Haenszel test was carried 
out to calculate the hazard ratios of death for the different 
treatments on tumor-bearing mice. All statistical analysis 
was completed using GraphPad Prism 6.
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